2024
Total Hip Arthroplasty in Patients Who Have Factor V Leiden: Elevated Risks Isolated to Venous Thromboembolism Events
Sanchez J, Jiang W, Dhodapkar M, Radford Z, Rubin L, Grauer J. Total Hip Arthroplasty in Patients Who Have Factor V Leiden: Elevated Risks Isolated to Venous Thromboembolism Events. The Journal Of Arthroplasty 2024, 39: 2421-2426. PMID: 38838962, DOI: 10.1016/j.arth.2024.05.083.Peer-Reviewed Original ResearchFactor V LeidenAdverse eventsChemoprophylactic agentV LeidenMultivariate analysisFactor V Leiden patientsTotal hip arthroplastyPatients to venous thromboembolismLog-rank testIncreased VTE riskVenous thromboembolic eventsElevated riskPerioperative adverse eventsPre-existing comorbiditiesAdministrative claims databaseInherited ThrombophiliaThromboembolic eventsElixhauser Comorbidity IndexAdult patientsVenous thromboembolismImplant survivalVTE riskComorbidity indexClaims databaseHip arthroplastyTotal shoulder arthroplasty in patients with factor V Leiden
Zehner K, Sanchez J, Dhodapkar M, Modrak M, Luo X, Grauer J. Total shoulder arthroplasty in patients with factor V Leiden. Journal Of Shoulder And Elbow Surgery 2024, 34: 18-25. PMID: 38479723, DOI: 10.1016/j.jse.2024.01.041.Peer-Reviewed Original ResearchFactor V LeidenVenous thromboembolismAdverse eventsV LeidenTSA patientsRevision rateProphylactic agentFactor V Leiden patientsVTE prophylactic agentOdds ratioRisk of venous thromboembolismEffective treatment optionOdds of bleeding complicationsDeep vein thrombosisMultivariate logistic regressionEnd-stage glenohumeral osteoarthritisTotal shoulder arthroplastyInherited ThrombophiliaBleeding complicationsElixhauser Comorbidity IndexLonger-term outcomesPulmonary embolismProthrombotic stateVein thrombosisAdult patients
2022
Risk factors for venous thromboembolism following fractures isolated to the foot and ankle fracture
Gouzoulis MJ, Joo PY, Kammien AJ, McLaughlin WM, Yoo B, Grauer JN. Risk factors for venous thromboembolism following fractures isolated to the foot and ankle fracture. PLOS ONE 2022, 17: e0276548. PMID: 36264985, PMCID: PMC9584400, DOI: 10.1371/journal.pone.0276548.Peer-Reviewed Original ResearchConceptsVenous thromboembolismAnkle fracturesFactor V LeidenSurgical treatmentRisk factorsActive cancerV LeidenTiming of VTEPrior venous thromboembolismIsolated footIndependent risk factorDeep vein thrombosisRisk/benefit considerationsMultivariate logistical regressionSpecific fracture patternsElixhauser indexPulmonary embolismVein thrombosisPearlDiver databaseMetatarsal fracturesAppendicular fracturesMale sexSuch injuriesTraumatic injuryChi-square analysis
2021
Factor V Leiden and the 10-year incidence of depression: A retrospective cohort study conducted in Germany
Jacob L, Jacob C, Koyanagi A, Smith L, Haro J, Shin J, Kostev K. Factor V Leiden and the 10-year incidence of depression: A retrospective cohort study conducted in Germany. Journal Of Psychiatric Research 2021, 146: 87-91. PMID: 34959163, DOI: 10.1016/j.jpsychires.2021.12.045.Peer-Reviewed Original ResearchConceptsFactor V LeidenDiagnosis of factor V LeidenRetrospective cohort studyIncidence of depressionV LeidenIndex dateCohort studyKaplan-Meier curvesCox regression analysisCox regression modelsLong-term risk factorsConsults per yearThromboembolic eventsIndex yearRisk factorsPatientsVisit dateGeneral practiceIncidenceCoxRegression analysisDiagnosisRegression modelsDepressionAssociation
2019
Whole-Exome Sequencing in Evaluation of Thrombophilia: Characterization of Novel Genetic Variants
Gu S, Shevell L, Tormey C, Rinder H, Lee A. Whole-Exome Sequencing in Evaluation of Thrombophilia: Characterization of Novel Genetic Variants. American Journal Of Clinical Pathology 2019, 152: s35-s35. DOI: 10.1093/ajcp/aqz112.066.Peer-Reviewed Original ResearchWhole-exome sequencingMultiple sequence alignment analysisVenous thromboembolismGenetic variantsSequence alignment analysisDisease-causing genetic variantsVon Willebrand factorRegions of proteinsNovel genetic variantsNext-generation sequencing studiesAmino acid substitutionsGenetic factorsNovel VUSAlignment analysisMajority of VTESequencing studiesAcid substitutionsSilico mutagenesisConformational changesEvaluation of thrombophiliaDeep venous thrombosisNonsynonymous variantsProthrombin gene mutationFactor V LeidenEnzymatic activity
2016
Thrombophilia and Pregnancy
Hendrix P, Tinelli A, Malvasi A, Paidas M. Thrombophilia and Pregnancy. 2016, 287-313. DOI: 10.1007/978-3-319-31377-1_13.Peer-Reviewed Original ResearchAdverse pregnancy outcomesPregnancy outcomesHereditary thrombophiliaBest practice clinical guidelinesContinuum of pregnancyVenous thromboembolic eventsRecurrent fetal lossIntrauterine growth restrictionProthrombin gene mutationNatural anticoagulant protein SFactor V LeidenEfficacy of preventionFetal morbidityThromboembolic eventsAntiphospholipid syndromeMaternal riskPuerperal periodClinical guidelinesFetal lossGrowth restrictionTreatment paradigmV LeidenRisk associationThrombophiliaPregnancyFactor V Leiden, prothrombin G20210A, and methylene tetrahydrofolate reductase mutations and stillbirth: the Stillbirth Collaborative Research Network
Silver RM, Saade GR, Thorsten V, Parker CB, Reddy UM, Drews-Botsch C, Conway D, Coustan D, Dudley DJ, Bukowski R, Hogue C, Pinar H, Varner MW, Goldenberg R, Willinger M. Factor V Leiden, prothrombin G20210A, and methylene tetrahydrofolate reductase mutations and stillbirth: the Stillbirth Collaborative Research Network. American Journal Of Obstetrics And Gynecology 2016, 215: 468.e1-468.e17. PMID: 27131585, DOI: 10.1016/j.ajog.2016.04.026.Peer-Reviewed Original ResearchConceptsFactor V LeidenStillbirth Collaborative Research NetworkCase-control studyHeritable thrombophiliaV LeidenProthrombin G20210AFetal thrombophiliaOdds ratioPAI-1 4G/4G polymorphismPopulation-based case-control studyMaternal factor V LeidenHomozygous factor V Leiden mutationFactor V Leiden mutationEvaluation of stillbirthTetrahydrofolate reductase mutationOdds of stillbirthV Leiden mutationTetrahydrofolate reductase C677TCollaborative research networksReductase C677TResearch NetworkMaternal thrombophiliaThrombophilia markersSingleton pregnanciesIncreased odds
2010
Factor V Leiden Mutation and Thromboembolism Risk in Women Receiving Adjuvant Tamoxifen for Breast Cancer
Garber JE, Halabi S, Tolaney SM, Kaplan E, Archer L, Atkins JN, Edge S, Shapiro CL, Dressler L, Paskett E, Kimmick G, Orcutt J, Scalzo A, Winer E, Levine E, Shahab N, Berliner N, B F. Factor V Leiden Mutation and Thromboembolism Risk in Women Receiving Adjuvant Tamoxifen for Breast Cancer. Journal Of The National Cancer Institute 2010, 102: 942-949. PMID: 20554945, PMCID: PMC2897879, DOI: 10.1093/jnci/djq211.Peer-Reviewed Original ResearchMeSH KeywordsAgedAntineoplastic Agents, HormonalBreast NeoplasmsCase-Control StudiesChemotherapy, AdjuvantEstrogen Receptor ModulatorsFactor VFemaleHumansLogistic ModelsMiddle AgedMultivariate AnalysisMutationOdds RatioPrevalenceRisk FactorsSelective Estrogen Receptor ModulatorsSmokingTamoxifenThromboembolismConceptsFactor V LeidenEarly-stage breast cancerThromboembolic eventsAdjuvant tamoxifenFVL mutationBreast cancerTamoxifen useTE riskControl subjectsOdds ratioFactor V Leiden mutationCase-control studyConditional logistic regressionV Leiden mutationPostmenopausal womenThromboembolism riskThrombosis riskMultivariable modelTherapeutic decisionsV LeidenLeiden mutationHigh riskPositive testTamoxifenCancer
2006
Inherited Thrombophilias and Early Pregnancy Loss
Langhoff-Roos J, Paidas M, Ku D, Arkel Y, Loekwood C. Inherited Thrombophilias and Early Pregnancy Loss. Medical Intelligence Unit 2006, 229-243. DOI: 10.1007/0-387-34944-8_20.Peer-Reviewed Original ResearchFactor V LeidenThrombophilic conditionsPregnancy complicationsClinical manifestationsV LeidenFirst trimester pregnancy outcomeHeterozygous factor V LeidenIntrauterine growth restrictionLate fetal lossEarly pregnancy lossMaternal thromboembolismThrombogenic mutationsAbruptio placentaePregnancy outcomesProthrombotic conditionsPregnancy lossFetal lossGrowth restrictionAntithrombin deficiencyClinical practiceHeterogeneous groupComplicationsThrombophiliaDominant conditionCurrent knowledge
2005
Arterial thrombosis associated with heterozygous factor V Leiden disorder, hyperhomocysteinemia, and peripheral arterial disease: Importance of synergistic factors
Page C, Rubin LE, Gusberg RJ, Dardik A. Arterial thrombosis associated with heterozygous factor V Leiden disorder, hyperhomocysteinemia, and peripheral arterial disease: Importance of synergistic factors. Journal Of Vascular Surgery 2005, 42: 1014-1018. PMID: 16275464, DOI: 10.1016/j.jvs.2005.06.019.Peer-Reviewed Case Reports and Technical NotesMeSH KeywordsAcute DiseaseAngiographyFactor VFactor V DeficiencyFibrinolytic AgentsFollow-Up StudiesHeparinHeterozygoteHumansHyperhomocysteinemiaInjections, Intra-ArterialMaleMiddle AgedMutationPeripheral Vascular DiseasesPopliteal ArteryThromboembolismThrombolytic TherapyTissue Plasminogen ActivatorConceptsPeripheral arterial diseaseArterial diseaseArterial thrombosisPre-existing peripheral arterial diseaseAcute popliteal artery thrombosisAcute arterial thrombosisPopliteal artery thrombosisIntra-arterial thrombolysisRisk factor modificationDeep venous thrombosisLong-term treatmentFactor V LeidenArtery thrombosisAcute thrombosisVenous thrombosisHomocysteine levelsFactor modificationV LeidenNormal limitsThrombosisHyperhomocysteinemiaFolic acidDiseaseDisordersAnticoagulation
2004
Epidural blood patch in a patient taking enoxaparin
Gaiser R, Berkowitz D, Chou D. Epidural blood patch in a patient taking enoxaparin. Journal Of Clinical Anesthesia 2004, 16: 386-388. PMID: 15374562, DOI: 10.1016/j.jclinane.2003.09.011.Peer-Reviewed Original ResearchFactor V Leiden and the Risk for Thromboembolism: Is Anticoagulation the Answer?
Gilleran S, Trow T. Factor V Leiden and the Risk for Thromboembolism: Is Anticoagulation the Answer? Clinical Pulmonary Medicine 2004, 11: 264-265. DOI: 10.1097/01.cpm.0000133056.55731.47.Peer-Reviewed Original Research
1998
Stroke in a Neonate Heterozygous for Factor V Leiden
Varelas P, Sleight B, Rinder H, Sze G, Ment L. Stroke in a Neonate Heterozygous for Factor V Leiden. Pediatric Neurology 1998, 18: 262-264. PMID: 9568926, DOI: 10.1016/s0887-8994(97)00166-5.Peer-Reviewed Original Research
1997
Activated protein C resistance and anticardiolipin antibodies in patients with venous leg ulcers
Grossman D, Heald P, Wang C, Rinder H. Activated protein C resistance and anticardiolipin antibodies in patients with venous leg ulcers. Journal Of The American Academy Of Dermatology 1997, 37: 409-413. DOI: 10.1016/s0190-9622(18)30738-2.Peer-Reviewed Original ResearchVenous leg ulcersFactor V Leiden mutationV Leiden mutationFactor V LeidenAnticardiolipin antibodiesLeg ulcersLeiden mutationV LeidenVenous leg ulcerationCommon risk factorsPartial thromboplastin timeAPC resistanceEnzyme-linked immunosorbentProtein C resistanceConsecutive patientsLeg ulcerationVenous thrombosisRisk factorsSkin ulcerationThromboplastin timeGeneral populationPatientsUlcersMethods TwentyLow APC ratioActivated protein C resistance and anticardiolipin antibodies in patients with venous leg ulcers
Grossman D, Heald P, Wang C, Rinder H. Activated protein C resistance and anticardiolipin antibodies in patients with venous leg ulcers. Journal Of The American Academy Of Dermatology 1997, 37: 409-413. PMID: 9308555, DOI: 10.1016/s0190-9622(97)70141-5.Peer-Reviewed Original ResearchConceptsVenous leg ulcersFactor V Leiden mutationV Leiden mutationFactor V LeidenAnticardiolipin antibodiesLeg ulcersLeiden mutationV LeidenVenous leg ulcerationCommon risk factorsPartial thromboplastin timeAPC resistanceEnzyme-linked immunosorbentProtein C resistanceConsecutive patientsHypercoagulable stateLeg ulcerationVenous thrombosisRisk factorsSkin ulcerationThromboplastin timeGeneral populationPatientsUlcersLow APC ratio
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply